elAttar T M, Lin H S
Laboratory of Hormone Research, University of Missouri-Kansas City, School of Dentistry 64108.
Prostaglandins Leukot Essent Fatty Acids. 1995 Jan;52(1):69-73. doi: 10.1016/0952-3278(95)90099-3.
Previous studies have shown that prostaglandin E2 (PGE2) and vitamin E succinate can act in an additive manner to inhibit the proliferation of human oral squamous carcinoma cells (SCC-25). The initial studies on the additive anticancer activity of PGE2 and vitamin E succinate have been extended to include antineoplastic PGs, delta 12-PGJ2 and PGJ2. Treatment of oral squamous carcinoma cells (SCC-15) with delta 12-PGJ2, PGJ2, and vitamin E succinate, individually, caused significant concentration-dependent inhibition of cell proliferation to various degrees. PGJ2 was most potent and caused an inhibition that corresponded to 85.55% at 10(-5) M. Addition of 1 microM of vitamin E succinate to delta 12-PGJ2 or PGJ2 resulted in a significant increase in the inhibitory potency of the lower concentrations of the two PGs. These results suggest a novel role for a mixture of PGs and vitamin E as potent antitumor proliferative agents.
先前的研究表明，前列腺素E2（PGE2）和琥珀酸维生素E可协同作用，抑制人口腔鳞状癌细胞（SCC - 25）的增殖。关于PGE2和琥珀酸维生素E协同抗癌活性的初步研究已扩展至包括抗肿瘤前列腺素δ12 - PGJ2和PGJ2。分别用δ12 - PGJ2、PGJ2和琥珀酸维生素E处理口腔鳞状癌细胞（SCC - 15），均能在不同程度上引起显著的浓度依赖性细胞增殖抑制。PGJ2的作用最强，在10(-5) M时可导致85.55%的抑制率。向δ12 - PGJ2或PGJ2中添加1 microM的琥珀酸维生素E，可显著提高这两种前列腺素较低浓度时的抑制效力。这些结果表明，前列腺素和维生素E的混合物作为有效的抗肿瘤增殖剂具有新的作用。
